Alkem Labs Q1 FY27 Consolidated Revenue at ₹3,740 Crore, Profit at ₹521 Crore
Alkem Laboratories reported consolidated revenue of ₹3,740.15 crore and profit after tax of ₹519.96 crore for Q1 FY27. Standalone revenue was ₹2,667.73 crore with profit after tax of ₹569.98 crore. The results were approved by the board on August 14, 2026.
The announcement of quarterly financial results is a routine but significant event for a publicly listed company. The positive performance is likely to be viewed favorably by investors, influencing stock price and investor sentiment.
The company reported positive financial results with increased revenue and profit compared to the previous year's quarter, indicating a healthy financial performance.
Alkem Laboratories Limited announced its financial results for the quarter ended June 30, 2026. The company reported consolidated revenue from operations of ₹37,401.5 million (₹3,740.15 crore) and other income of ₹1,527.5 million (₹152.75 crore), leading to a total income of ₹38,929.0 million (₹3,892.90 crore).
Total expenses for the quarter amounted to ₹31,209.1 million (₹3,120.91 crore). The company recorded a profit before exceptional items and tax of ₹7,719.9 million (₹771.99 crore). After considering exceptional items of ₹(1,349.7) million (₹(134.97) crore) and tax expenses of ₹2,505.0 million (₹250.50 crore), the profit for the period attributable to the owners of the company stood at ₹5,199.6 million (₹519.96 crore).
On a standalone basis, Alkem Laboratories reported revenue from operations of ₹26,677.3 million (₹2,667.73 crore) and total income of ₹28,043.5 million (₹2,804.35 crore). Total expenses were ₹20,059.3 million (₹2,005.93 crore), resulting in a profit before exceptional items and tax from continuing operations of ₹7,984.2 million (₹798.42 crore). After accounting for tax expenses of ₹2,284.4 million (₹228.44 crore), the profit for the period from continuing operations attributable to owners of the company was ₹5,699.8 million (₹569.98 crore). The company also reported profits from discontinued operations.
The Board of Directors approved these standalone and consolidated un-audited financial results at a meeting held on August 14, 2026. The company's financial statements were reviewed by Deloitte Haskins & Sells LLP, Chartered Accountants, who issued an unmodified review report.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.